On the other hand, in an attempt to find predictive biomarkers for a neo-adjuvant therapy for stage II–III EGFR-mutated NSCLC, exon 4/5 TP53 missense mutations have been found to be a stratification factor for OS and treatment [109]; another study based on the IALT trial case series, found that TP53 mutations play a role in predicting the efficacy of adjuvant platinum-based chemotherapy [110]. Here, TP53 is linked to non-small cell lung carcinoma.